Company research
Scopus BioPharma Inc.
CIK 1772028Updated Sep 27, 2026
SecuritySCPS · OTC · equity
SCPS price & chart
Loading TradingView…
OTC:SCPS on TradingView ↗In the news
No coverage from other publishers is available.
Recent filings
No filing activity has been returned.
Financials
FY 2022 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 392,265Source | 8,187,715Source | 1,974,068Source | 771,682Source |
| Property, Plant and Equipment, NetUSD | 2,265Source | 2,840Source | 2,329Source | 3,659Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 124,575Source | 7,942,971Source | 1,832,100Source | 36,747Source |
| Assets, CurrentUSD | 390,000Source | 8,184,875Source | 1,971,739Source | 768,023Source |
| Prepaid Expense and Other Assets, CurrentUSD | 265,425Source | 241,904Source | 139,639Source | 104,260Source |
| LIABILITIES AND EQUITY | ||||
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 21,094Source | 21,094Source | 14,578Source | 12,509Source |
| Additional Paid in CapitalUSD | 46,518,455Source | 45,538,156Source | 14,224,000Source | 3,577,533Source |
| Retained Earnings (Accumulated Deficit)USD | -53,064,975Source | -41,455,148Source | -14,501,739Source | -3,639,447Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -4,954Source | -86,653Source | -68,067Source | -33,454Source |
| Stockholders' Equity Attributable to ParentUSD | -6,564,330Source | 4,017,449Source | -1,831,228Source | -82,859Source |
| Liabilities and EquityUSD | 392,265Source | 8,187,715Source | 1,974,068Source | 771,682Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 7,454,434Source | 4,170,266Source | 3,805,296Source | 854,541Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | -497,839Source | — | — | — |
cash flow · annual statements
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -11,714,877Source | -26,953,409Source | 10,862,292Source | 2,689,949Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 351,721Source | 669,602Source | 270,407Source | 213,649Source |
| Deferred Income Tax Expense (Benefit)USD | 4,118,399Source | 5,669,348Source | 1,771,397Source | 839,286Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -8,126,628Source | -11,424,637Source | -2,525,289Source | -2,120,402Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Property, Plant, and EquipmentUSD | 1,552Source | 1,999Source | 0Source | 4,251Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 241,942Source | 17,556,768Source | 4,352,735Source | 2,183,713Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -7,818,396Source | 6,110,871Source | 1,795,353Source | 35,087Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 124,575Source | 7,942,971Source | — | — |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 0Source | 25,043Source | 470Source | 0Source |
| Income Taxes Paid, NetUSD | — | 0Source | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 351,721Source | 669,602Source | 270,407Source | 124,498Source |
| Amortization of Debt Issuance CostsUSD | — | — | 95,305Source | — |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | 606,104Source | 549,962Source | 0Source |
| DepreciationUSD | 1,728Source | 1,500Source | 1,440Source | 664Source |
| General and Administrative ExpenseUSD | 9,033,132Source | 12,611,169Source | 2,732,060Source | 2,226,837Source |
| Net Income (Loss) Attributable to ParentUSD | -11,609,827Source | -26,953,409Source | -10,862,292Source | -2,689,949Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -105,050Source | — | — | — |
| Operating ExpensesUSD | 11,714,877Source | 27,634,619Source | 10,155,846Source | 2,689,949Source |
| Other Nonoperating Income (Expense)USD | — | 681,210Source | — | — |
| Proceeds from Issuance of Common StockUSD | 0Source | 20,100,000Source | 3,162,500Source | 0Source |
| Proceeds from Noncontrolling InterestsUSD | 241,942Source | — | — | — |
income statement · annual statements
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Total RevenueUSD | 0Source | 0Source | 0Source | 0Source |
| Operating Income (Loss)USD | -11,714,877Source | -27,634,619Source | -10,155,846Source | -2,689,949Source |
| Other Nonoperating Income (Expense)USD | — | 681,210Source | — | — |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -105,050Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -11,609,827Source | -26,953,409Source | -10,862,292Source | -2,689,949Source |
| Earnings Per Share, BasicUSD per share | -0.55Source | -1.56Source | — | — |
| Earnings Per Share, DilutedUSD per share | -0.55Source | -1.56Source | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 21,094,264Source | 17,252,391Source | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 21,094,264Source | 17,252,391Source | — | — |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | — | 5,996Source | 352Source | — |
| General and Administrative ExpenseUSD | 9,033,132Source | 12,611,169Source | 2,732,060Source | 2,226,837Source |
| Interest ExpenseUSD | 0Source | 774,679Source | 706,446Source | 0Source |
| Interest Expense, DebtUSD | 0Source | 774,679Source | 705,976Source | — |
| Operating ExpensesUSD | 11,714,877Source | 27,634,619Source | 10,155,846Source | 2,689,949Source |
| Research and Development ExpenseUSD | 2,681,745Source | 15,023,450Source | 7,423,786Source | 463,112Source |